Counterpoint Mutual Funds LLC Has $443,000 Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Counterpoint Mutual Funds LLC lifted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 20.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,341 shares of the company’s stock after buying an additional 3,065 shares during the quarter. Counterpoint Mutual Funds LLC’s holdings in Hims & Hers Health were worth $443,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of HIMS. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health during the fourth quarter worth $28,000. Raleigh Capital Management Inc. grew its holdings in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. grew its holdings in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC grew its holdings in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares during the period. Finally, US Bancorp DE grew its holdings in Hims & Hers Health by 346.7% in the fourth quarter. US Bancorp DE now owns 1,943 shares of the company’s stock worth $47,000 after purchasing an additional 1,508 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the transaction, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $29.98, for a total transaction of $126,305.74. Following the completion of the transaction, the chief financial officer now owns 128,365 shares of the company’s stock, valued at $3,848,382.70. The trade was a 3.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 890,592 shares of company stock worth $31,677,291 over the last quarter. Corporate insiders own 17.71% of the company’s stock.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of research reports. Leerink Partners raised their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday, February 25th. Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Finally, Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $37.23.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $34.68 on Tuesday. The firm has a market cap of $7.70 billion, a price-to-earnings ratio of 78.82 and a beta of 1.37. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The firm’s 50-day simple moving average is $38.64 and its two-hundred day simple moving average is $28.37.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.